blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3328887

EP3328887 - ANTI-GM-CSF ANTIBODIES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.06.2022
Database last updated on 20.09.2024
FormerThe patent has been granted
Status updated on  16.07.2021
FormerGrant of patent is intended
Status updated on  10.06.2021
FormerExamination is in progress
Status updated on  22.11.2019
FormerRequest for examination was made
Status updated on  04.05.2018
FormerThe international publication has been made
Status updated on  24.03.2018
Formerunknown
Status updated on  23.02.2018
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
I-Mab Biopharma (Hangzhou) Co., Ltd.
6F, No.3 Bld., Hexiang Technology Center
Qiantang New Area
Hangzhou
Zhejiang / CN
[2021/25]
Former [2020/12]For all designated states
I-Mab Biopharma Co., Ltd.
Rm802, 8F, 1Bld., West Tower
88 Shangke Rd.
Pudong
Shanghai, 201210 / CN
Former [2019/50]For all designated states
I-Mab Biopharma US Limited
9801 Washingtonian Blvd, Suite 710
Gaithersburg, MD 20878 / US
Former [2018/23]For all designated states
I-MAB
Grand Pavilion, Hibiscus Way
802 West Bay Road
PO Box 31119
Cayman KY1-1205 / KY
Inventor(s)01 / WANG, Zhengyi
Suite 802, West Tower
OmniVision Tech Park
88 Shangke Road
Pudong New District
Shanghai 201210 / CN
02 / FANG, Lei
Suite 802, West Tower
OmniVision Tech Park
88 Shangke Road
Pudong New District
Shanghai 201210 / CN
03 / GUO, Bingshi
Suite 802, West Tower
OmniVision Tech Park
88 Shangke Road
Pudong New District
Shanghai 201210 / CN
04 / ZANG, Jingwu
Suite 802, West Tower
OmniVision Tech Park
88 Shangke Road
Pudong New District
Shanghai 201210 / CN
 [2019/21]
Former [2018/23]01 / WANG, Zhengyi
Suite 219
Building 6
Chamtime Plaza
2889 Jingke Road
Shanghai 201206 / CN
02 / FANG, Lei
Suite 219
Building 6
Chamtime Plaza
2889 Jingke Road
Shanghai 201206 / CN
03 / GUO, Bingshi
Suite 219
Building 6
Chamtime Plaza
2889 Jingke Road
Shanghai 201206 / CN
04 / ZANG, Jingwu
Suite 219
Building 6
Chamtime Plaza
2889 Jingke Road
Shanghai 201206 / CN
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/33]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2018/23]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date17840546.018.09.2017
[2018/23]
WO2017CN102057
Priority number, dateCN20161083152519.09.2016         Original published format: CN201610831525
CN20161083267719.09.2016         Original published format: CN201610832677
[2018/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018050111
Date:22.03.2018
Language:EN
[2018/12]
Type: A1 Application with search report 
No.:EP3328887
Date:06.06.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 22.03.2018 takes the place of the publication of the European patent application.
[2018/23]
Type: B1 Patent specification 
No.:EP3328887
Date:18.08.2021
Language:EN
[2021/33]
Search report(s)International search report - published on:CN22.03.2018
(Supplementary) European search report - dispatched on:EP04.03.2019
ClassificationIPC:A61K39/00, C07K16/24, A61P37/06, A61P35/00
[2021/17]
CPC:
A61P19/02 (EP,IL,US); C07K16/24 (IL,US); C07K16/243 (EP,IL,KR,US);
A61K39/395 (IL); A61K39/3955 (IL,US); A61P29/00 (EP,IL,US);
A61P35/00 (EP,IL,US); A61P35/02 (EP,IL,US); A61P37/02 (EP,IL,US);
A61P37/06 (EP,IL,US); G01N33/6863 (EP,IL,US); G01N33/6893 (KR);
A61K2039/505 (EP,KR,US); C07K2317/24 (EP,IL,KR,US); C07K2317/30 (EP,US);
C07K2317/31 (KR); C07K2317/33 (EP,US); C07K2317/565 (KR);
C07K2317/622 (KR); C07K2317/73 (EP,US); C07K2317/75 (IL);
C07K2317/76 (EP,US); C07K2317/92 (EP,IL,US); C07K2317/94 (EP,US);
G01N2333/535 (EP,IL,KR,US) (-)
Former IPC [2018/23]C07K16/24, C12N15/13, A61K39/395, A61P29/00, A61P35/00, A61P37/02, A61P35/02, A61P19/02, G01N33/577, G01N33/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/23]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ANTI-GM-CSF-ANTIKÖRPER UND VERWENDUNGEN DAFÜR[2018/23]
English:ANTI-GM-CSF ANTIBODIES AND USES THEREOF[2018/23]
French:ANTICORPS ANTI-GM-CSF ET LEURS UTILISATIONS[2018/23]
Entry into regional phase22.02.2018National basic fee paid 
22.02.2018Search fee paid 
22.02.2018Designation fee(s) paid 
22.02.2018Examination fee paid 
Examination procedure22.02.2018Examination requested  [2018/23]
22.02.2018Date on which the examining division has become responsible
30.09.2019Amendment by applicant (claims and/or description)
26.11.2019Despatch of a communication from the examining division (Time limit: M04)
31.03.2020Reply to a communication from the examining division
30.04.2020Despatch of a communication from the examining division (Time limit: M04)
11.08.2020Reply to a communication from the examining division
23.03.2021Cancellation of oral proceeding that was planned for 15.04.2021
15.04.2021Date of oral proceedings (cancelled)
11.06.2021Communication of intention to grant the patent
06.07.2021Fee for grant paid
06.07.2021Fee for publishing/printing paid
06.07.2021Receipt of the translation of the claim(s)
Opposition(s)19.05.2022No opposition filed within time limit [2022/30]
Fees paidRenewal fee
27.08.2019Renewal fee patent year 03
09.09.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL18.08.2021
CY18.08.2021
EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
MT18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
IE18.09.2021
LU18.09.2021
BG18.11.2021
IS18.12.2021
[2024/41]
Former [2024/23]AL18.08.2021
CY18.08.2021
EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
IE18.09.2021
LU18.09.2021
BG18.11.2021
IS18.12.2021
Former [2023/30]AL18.08.2021
CY18.08.2021
EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
IE18.09.2021
LU18.09.2021
BG18.11.2021
IS18.12.2021
Former [2022/36]AL18.08.2021
EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
IE18.09.2021
LU18.09.2021
BG18.11.2021
IS18.12.2021
Former [2022/35]AL18.08.2021
EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SK18.08.2021
SM18.08.2021
IE18.09.2021
LU18.09.2021
BG18.11.2021
IS18.12.2021
Former [2022/34]AL18.08.2021
EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SK18.08.2021
SM18.08.2021
LU18.09.2021
BG18.11.2021
IS18.12.2021
Former [2022/27]AL18.08.2021
EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/26]EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/24]EE18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
RO18.08.2021
RS18.08.2021
SK18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/10]HR18.08.2021
LT18.08.2021
LV18.08.2021
RS18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/09]LT18.08.2021
RS18.08.2021
BG18.11.2021
Former [2022/08]LT18.08.2021
BG18.11.2021
Documents cited:Search[I]WO2007092939  (MORPHOTEK INC [US], et al) [I] 1-14 * paragraphs [0019] - [0021] - [0042] , [0043] , [0054] - [0056] - [0139] - [0141] *;
 [I]WO2008064321  (KALOBIOS PHARMACEUTICALS INC [US], et al) [I] 1-15 * paragraphs [0009] - [0021] - [0022] - [0042] - [0122] - [0133]; tables 1,2 *;
 [I]WO2008141391  (CRC FOR ASHTMA AND AIRWAYS LTD [AU], et al) [I] 1-12 * pages 2-5; tables 1,2 * * page 9, line 10 - page 11, line 21 * * examples 1-3,5,6; table 7 *;
 [I]WO2010071923  (UNIV MELBOURNE [AU], et al) [I] 1-11,15 * paragraphs [0011] - [0020] - [0031] , [0034] , [0038] , [0039] , [0052]; examples 2-6,8-11 *;
 [I]WO2010124163  (THERACLONE SCIENCES INC [US], et al) [I] 1-14 * paragraphs [0105] , [0106] , [0121] - [0127]; examples 1,2,7 *;
 [I]WO2011153592  (CRC FOR ASTHMA AND AIRWAYS LTD [AU], et al) [I] 1-12 * page 2, line 8 - page 5, line 22 * * page 12, line 16 - page 13, line 10 * * page 15, lines 2-14 * * page 15, line 16 - page 16, line 14; examples 1,2,4 *;
 [I]US8268311  (KIRCHNER JACQUELINE A [US], et al) [I] 1-12 * column 3, line 60 - column 9, line 59; examples 1-2,4,5,6 *;
 [I]EP2535353  (EVEC INC [JP], et al) [I] 1-12 * paragraphs [0010] - [0015] - [0037] , [0252] - [0335]; tables A,B *;
 [I]US2014065163  (MAGNENAT LAURENT [CH], et al) [I] 1-12 * paragraphs [0001] - [0013] - [0028] - [0032] - [0061] - [0063] - [0080] - [0082] - [0088] - [0089] *;
 [I]WO2014138862  (SCHRADER JOHN [CA]) [I] 1-15 * paragraphs [0012] , [0013] , [0019] , [0023] - [0027] - [0059] - [0061] - [0104] - [0106]; table 2 *;
 [I]WO2015028657  (TAKEDA GMBH [DE]) [I] 1-12,15 * page 2, line 18 - page 7, line 20 * * page 28, line 14 - page 89, line 5 *;
 [I]  - CRIS S. CONSTANTINESCU ET AL, "Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis", NEUROLOGY - NEUROIMMUNOLOGY NEUROINFLAMMATION, (20150521), vol. 2, no. 4, doi:10.1212/NXI.0000000000000117, page e117, XP055540931 [I] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.1212/NXI.0000000000000117
 [I]  - PULJIC ET AL, "Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF", EUROPEAN JOURNAL OF PHARMACO, ELSEVIER SCIENCE, NL, (20070203), vol. 557, no. 2-3, doi:10.1016/J.EJPHAR.2006.11.023, ISSN 0014-2999, pages 230 - 235, XP005872830 [I] 1-12 * abstract * * paragraphs [02.4] , [02.5] , [03.4] , [03.5] , [0004] *

DOI:   http://dx.doi.org/10.1016/j.ejphar.2006.11.023
 [I]  - KRINNER E M ET AL, "A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF", MOLECULAR IMMUNOL, PERGAMON, GB, vol. 44, no. 5, doi:10.1016/J.MOLIMM.2006.03.020, ISSN 0161-5890, (20070201), pages 916 - 925, (20060511), XP005663412 [I] 1-12 * abstract * * paragraphs [02.1] , [02.5] , [02.6] , [03.1] , [03.2] , [03.3] , [03.5] , [03.7] , [0004] *

DOI:   http://dx.doi.org/10.1016/j.molimm.2006.03.020
 [I]  - FRANK BEHRENS ET AL, "First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial", ARTHRITIS & RHEUMATISM; ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY AND ASSOCIATION-OF-RHEUMATOLOGY-HE; WASHINGTON, DC, USA; NOVEMBER 10 -14, 2012, WILEY INTERSCIENCE, US, vol. 64, no. 12, ISSN 0004-3591, (20121201), pages 4171 - 4172, (20121128), XP002733081 [I] 1-12 * abstract *
 [A]  - AOI SHIOMI ET AL, "GM-CSF as a therapeutic target in autoimmune diseases", INFLAMMATION AND REGENERATION, (20160705), vol. 36, no. 8, doi:10.1186/s41232-016-0014-5, pages 1 - 9, XP055338930 [A] 12 * the whole document *

DOI:   http://dx.doi.org/10.1186/s41232-016-0014-5
 [A]  - HAMILTON J A, "GM-CSF in inflammation and autoimmunity", TRENDS IN IMMUNO, ELSEVIER LTD. * TRENDS JOURNALS, GB, (20020801), vol. 23, no. 8, doi:10.1016/S1471-4906(02)02260-3, ISSN 1471-4906, pages 403 - 408, XP004371500 [A] 12 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1471-4906(02)02260-3
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.